Becton Dickinson & Co. closed 28.21% short of its 52-week high of $251.99, which the company reached on February 3rd.

The US Food and Drug Administration granted clearances for infectious disease tests, digital pathology software, and hematology analyzers, among other in vitro diagnostic technologies.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, ...

Affected Alaris products may have been serviced with previously recalled bezel kit assemblies. BD in 2019 recalled those kit ...

According to Benzinga Pro, Becton Dickinson's peer group average for short interest as a percentage of float is 4.29%, which ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Waters Corporation is merging with BD’s Biosciences and Diagnostic Solutions business in a $17.5 billion deal to expand its capabilities in life sciences and diagnostics.

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund underperformed its benchmark, the MSCI World Index (net), in the second ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Medical analysis equipment maker Waters is combining with a unit of Becton Dickinson in a complex spin-merge. At a discount ...

Kirkland & Ellis advises Waters on $17.5B merger with Becton Dickinson, creating a diagnostics and life sciences leader.